LBA59 – LMS-04 study: A randomised, multicenter, phase III study comparing doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin in non-progressive patients as first-line therapy, in patients with metastatic or unresectable leiomyosarcoma – A French Sarcoma Group study - Pautier, P; Italiano, A; Piperno-Neumann, S (Ann Oncol, 2021)
et al.